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High total plasma homocysteine (tHcy) has been associated with cognitive impairment in later
life, but it is unclear if this association is causal or is due to confounding. The C677T
polymorphism of the 5,10 methylenetetrahydrofolate reductase gene (MTHFR) increases basal
tHcy, but its contribution to cognitive impairment has not been established. We designed this
study to determine if tHcy is causally related to cognitive impairment in later life by
investigating its association with high tHcy and the MTHFR-C677T polymorphism. We
recruited 1778 older men from the Health in Men Study cohort and established caseness on
the basis of the participants’ scores on a Telephone Interview for Cognitive Status score p27
in 2008. Exposure to tHcy, gene status and other variables of interest were obtained from
assessments 4–7 years earlier. Multivariate logistic regression showed that the odds of
cognitive impairment increased with a doubling of tHcy (adjusted odds ratio, OR 1.36;
95% confidence interval, 95% CI 1.02–1.82). Compared with the wild CC genotype, participants
with the MTHFR-TT genotype had 46% greater odds of cognitive impairment (OR 1.46, 95% CI
1.01–2.11, P=0.043). The results of this study are consistent with, but do not prove the
hypothesis that high tHcy causes cognitive impairment in later life.
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Introduction
Current estimates suggest that over 80 million people
worldwide will be affected by dementia by 2040.
1
This is an alarming prospect, given that treatments
seem unable to reverse or halt the deficits associated
with this group of diseases. High total plasma
homocysteine (tHcy) has been associated with cogni-
tive impairment and dementia in observational
studies, offering hope that by reducing tHcy with
oral supplementation of specific B-vitamins we may
succeed in delaying the progression of cognitive
decline and the onset of dementia.
2
A number of observational studies have reported an
association between high tHcy and cognitive impair-
ment, but results to date have been inconsistent and
the nature of this research makes it difficult to draw
any firm conclusions about causality.
3–7 For example,
Luchsinger et al.
8 found that the risk of incident
Alzheimer’s disease (AD, the most frequent cause
of dementia) was twice as large amongst people in
the highest compared with the lowest tHcy quartile
(hazard ratio, HR=2.0, 95% confidence interval, 95%
CI=1.2–3.5), but such an association disappeared
once the analyses were adjusted for the joint effects of
age, gender, education, apolipoprotein-E status and
a history of stroke (HR=1.3, 95% CI=0.8–2.3). In
contrast, longitudinal data derived from the Framing-
ham study sample of 1092 people showed that the
relative risk of dementia increased by about 40%
(95% CI=10–90%) for each increase of one standard
deviation in the log-transformed tHcy concentration.
9
These analyses were adjusted for age, gender, apoli-
poprotein-E status, folate, vitamin B12 and B6 and
other vascular risk factors.
Randomized trials of homocysteine lowering treat-
ment for older people without dementia have not been
able to demonstrate an improvement in cognitive
performance associated with the use of B-vitamins,
10–12
although the largest and longest randomized trial
published to date found that the use of folic acid
improved cognition compared with placebo.
13 Received 29 July 2010; revised 25 January 2011; accepted 30
January 2011; published online 1 March 2011
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tively-randomized trials recruiting healthy volunteers
at low risk of developing cognitive impairment, using
B-vitamins of inadequate dose and duration, evaluat-
ing cognitive function by means of insensitive or
invalid measures and lacking statistical power to
reliably detect small, but clinically important effect
sizes. To date, no trials have been sufficiently
powered to investigate the effect of homocysteine
lowering treatment in dementia prevention (rather
than small changes in the normal range of cognitive
function).
Homocysteine metabolism is dependent on a
number of enzymes and vitamin co-factors. Methyle-
netetrahydrofolate reductase (MTHFR) is an enzyme
involved in the remethylation of homocysteine to
methionine. A common genetic polymorphism exists
in which cytosine is replaced by thymine (C-T) at
base position 677.
14 This polymorphism results in
reduced enzymatic activity and a 20% increase in
basal plasma tHcy.
15 Of note, the TT genotype has
been associated with poorer cognitive performance
and increased risk of dementia,
16–19 albeit not con-
sistently.
20,21 The advantage of examining the
MTHFR-C677T polymorphism in people with cogni-
tive impairment is that this association is not
confounded by other factors that affect tHcy, such as
age, lifestyle, medications and comorbidities.
22 This
approach has been termed Mendelian randomization,
as the exposure commences at conception and is
unconfounded by environmental factors, effectively
producing random exposure to the biological factor of
interest. One of the limitations of Mendelian rando-
mization is that other factors may affect the pheno-
type (in this case, cognitive function) through gene–
environment or gene–gene interactions. As a result,
gene–phenotype associations are not simple. None-
theless, if such a link could be confirmed, this would
underscore the validity of the association between
high tHcy and cognitive impairment, and would
support the use of B-vitamins to decrease the
incidence of dementia in later life.
23
We designed the present study to determine if
elevated tHcy and the MTHFR-C677T polymorphism
are associated with cognitive impairment in a com-
munity sample of 1778 older men. We hypothesized
that the odds of cognitive impairment would increase
with plasma tHcy and would be greatest in men with
tHcy X15mmol/l and those with the MTHFR-TT
genotype.
Methods
Study design
This is a case-control study of older men recruited as
part of the Health in Men Study cohort.
24
Setting and participants
The Health in Men Study originated from a popula-
tion-based trial of screening for abdominal aortic
aneurysm in Perth, Western Australia, between 1996
and 1998. Between 2001 and 2004, 4249 men
completed a health assessment and donated a blood
sample (baseline for this study). Men were commu-
nity-dwelling Australian citizens, recruited through
the electoral roll (voting being compulsory in Aus-
tralia). We excluded participants not fluent in written
or spoken English. Surviving participants (661 had
died) were contacted from August to December 2008
and invited to complete the Telephone Interview for
Cognitive Status (TICS).
25 We excluded from this
assessment men with a total score of 23 or less on the
Mini-Mental State Examination (MMSE) at baseline
(prevalent cases of cognitive impairment).
26 Men who
survived till 2008 and scored 27 or less on the TICS
were selected as the cases and the remaining partici-
pants were selected as the controls—they were all free
of significant hearing impairment—as determined by
their ability to communicate effectively with others
on the telephone (for example, able to understand and
respond appropriately and promptly to instructions).
Figure 1 shows the flow of participants from baseline
to the time of assessment with the TICS.
Baseline measurements of exposure to tHcy
We collected fasting blood samples from participants
at baseline between 0830 and 1100h. Plasma and
Attended baseline
survey 2001-
2004, n=4 263
(4 249 provided a
blood sample)
Declined
participation
or unable to
be contacted
(n=1 625)
Excluded due to
pre-existing
cognitive
impairment
(n=185)
Completed TICS in
2008 and had donated
a blood sample
between 2001-2004
(n=1 963)
Died before
TICS (n=661)
Participants
available for this
analysis (n=1 778)
Figure 1 Flow of participants from the time of collection of
blood samples to establishment of the presence of cognitive
impairment.
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blood collection and stored at  801C until assayed.
Total plasma homocysteine concentration was deter-
mined by reverse-phase high-performance liquid
chromatography after treatment with tributylpho-
sphine, deproteinization and fluorogenic derivatiza-
tion, using the method of Araki and Sako.
27 The
coefficient of variation ranged from 3 to 7%. Men
with tHcy X15mmol/l were considered to have high
tHcy.
Genomic DNA was isolated from nucleated blood
cells through a Triton X-100 method, and the C677T
polymorphism determined using polymerase chain
reaction and HinfI restriction enzyme digestion, as
previously described.
28 HinfI digestion (1.5-U/25ml
reaction mixture) was performed directly in the
polymerase chain reaction tube at 371C for 4h, before
analysis of restriction fragments by polyacrylamide
gel electrophoresis (12% T, 3.3% C). Allele frequen-
cies were estimated by gene counting, and observed
numbers of each genotype were compared with those
expected under the Hardy–Weinberg equilibrium.
Other baseline measures
At the baseline assessment, we used standard proce-
dures to collect the following information from
participants: age (in years), highest educational
achievement, smoking (past or current), risky alcohol
use (X15 standard units per week), physical activity
(X150min per week of vigorous or non-vigorous
physical activity) and physician diagnosis of stroke,
diabetes, ischemic heart disease, head injury or
hypertension. We used the 15-item Geriatric Depres-
sion Scale (GDS-15)
29 to assess depressive symptoms
and measured blood pressure (within 2mmHg),
height (in meters, to 0.01m) and weight (in kg, to
0.1kg). We calculated the body mass index (BMI)
in kg/m
2.
Fasting blood samples were used to measure serum
glucose, thyroid stimulating hormone, cholesterol,
low-density lipoprotein and triglycerides with a
Roche Hitachi 917 analyzer (Roche Diagnostics).
Serum triglycerides were estimated by the Friedewald
equation.
30 Serum creatinine was measured by Jaffe
kinetic reaction on a Roche 917 analyzer, and the
estimated glomerular filtration rate was calculated
using the Cockcroft-Gault equation:
½ð140   ageÞ wtðkgÞ =ðplasmacreatinine 0:8136Þ:
Outcomes
The primary outcome of interest in this study was
cognitive impairment, as defined by a total score of 27
or less on the TICS, as measured in 2008.
Statistical analysis
Data was analyzed with the statistical package Stata
11.1 (StataCorp 2009, TX, USA). Descriptive statistics
were used to analyze cross-sectional data, reporting
these as frequencies (%) and means with standard
deviations. Student t-tests were used in the analysis
of normally distributed data, the Mann–Whitney U-
tests in the analysis of ranked data and chi-square
tests to compare proportions between groups. Analy-
sis of variance was used to compare differences
between the MTHFR genotypes for continuous vari-
ables. Skewed data (age, tHcy, GDS, triglycerides and
thyroid stimulating hormone) were log-transformed to
perform the analysis of variance and reported as the
geometric mean. Multivariate logistic regression was
used to investigate the association between tHcy and
cognitive impairment, and the results are reported as
ORs with 95% confidence limits. Three models were
used: the first contained no adjustments (crude
model), the second model was adjusted for age and
education only, and the final model was adjusted for
all measured factors described above.
Total plasma homocysteine was included as a
continuous variable and dichotomized into plasma
concentrations X15mmol/l compared to those with
tHcy <15mmol/l. As tHcy was positively skewed, we
transformed these values into binary logs by dividing
the natural log-transformed value of tHcy by the
natural log of 2. Logistic regression performed using
these values will give ORs for a doubling of tHcy. We
tested the genotype distribution of MTHFR for
deviations from the Hardy–Weinberg equilibrium
using the exact method.
Total plasma homocysteine increases markedly
with age,
31 therefore quartiles were defined in an
age-specific manner for each of the four 5-year age
categories (that is, 75–79 (reference), 80–84, 85–90
and 90þ). We used multivariate logistic regression to
analyze these age-specific quartiles using the lowest
quartile as the reference group. Finally, we performed
a logistic regression analysis to determine the odds of
cognitive impairment according to MTHFR-C677T
genotypes (CC genotype used as reference).
Results
Participants
A total of 1778 men were included in this study. Of
these, 431 men scored p27 on the TICS (cases of
cognitive impairment). All other available partici-
pants were included in this study as controls.
Cross-sectional data
Characteristics of the study population are shown in
Table 1. Men with cognitive impairment were on
average 1.5 years older (z= 7.21, P<0.001). They
were also less educated (w
2=53.44, P<0.001), had
more depressive symptoms (z= 4.07, P<0.001) and
were more likely to report a history of diabetes
(w
2=8.34, P=0.004) and hypertension (w
2=6.47,
P=0.011). The mean tHcy was 0.7mmol/l lower in
controls (z= 3.75, P<0.001). In all, 376 men (21.1%)
had high tHcy and this was more frequent in
participants with cognitive impairment (w
2=8.77,
P=0.003). The groups were comparable for other
measured factors, such as physical activity, history of
MTHFR-C677T polymorphism and cognitive impairment
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smoking, alcohol use, lipid profile and BMI.
Main results
The distribution of the MTHFR polymorphism was
similar for each of the groups: CC 564 (46.2%), CT 531
(43.5%) and TT 127 (10.4%) in the controls and CC
158 (41.8%), CT 168 (44.4%) and TT 52 (13.8%) in
the cases (w
2=4.20, P=0.123). Baseline characteristics
were equally distributed across the MTHFR-C677T
genotypes (Table 2). Mean tHcy concentration varied
according to the MTHFR genotype: 11.8±1.3mmol/l,
12.3±1.4mmol and 12.5±1.5mmol/l for men with the
CC, CT and TT genotype, respectively (F=4.77,
P=0.009). The distribution of MTHFR-C677T geno-
types was as expected, given the Hardy–Weinberg
equilibrium test (P=0.504 for cases and P=0.896 for
controls).
The odds of cognitive impairment increased with
every 1mmol/l increase of tHcy (OR 1.03, 95% CI
1.01–1.05, P=0.006) (Table 3). Individuals with
elevated tHcy were also more likely to develop
cognitive impairment (OR 1.47, 95% CI 1.14–1.89,
P=0.003). The odds of cognitive impairment
increased with a doubling of tHcy (OR 1.59, 95% CI
1.24–2.03, P<0.001), and this association remained
significant after adjustments were made for age
and education (OR 1.37, 95% CI 1.06–1.78) and other
measured factors (OR 1.36, 95% CI 1.02–1.82).
Participants with the MTHFR-TT genotype had
greater odds of cognitive impairment (OR 1.46, 95%
CI 1.01–2.11, P=0.043) compared with the CC
genotype.
The 75th percentile of tHcy for each 5-year age
group was as follows: 75–79 (13.6mmol/l), 80–84
(14.7mmol/l), 85–89 (16.0mmol/l) and 90þ
(15.9mmol/l). Men in the highest tHcy quartile of
their specific age group (lowest quartile as reference
group) had 40% higher odds of cognitive impairment
(OR 1.40; 95% CI 1.03–1.91, P=0.032). This differ-
ence remained significant after adjustment for all
measured factors (OR 1.59, 95% CI 1.10–2.28).
Post-hoc analysis
We performed post-hoc analyses to clarify if any bias
was introduced because of the loss of men through
non-participation or death. Participants who died
before participation in the TICS (n=661) were on
average 2.8 years older (z= 15.23, P<0.001), had
higher mean tHcy concentrations (15.3 vs 12.8mmol/l,
z= 9.76, P<0.001) and lower mean MMSE scores at
the time of blood collection (25.9 vs 27.3, t=14.39,
P<0.001) than those who completed the TICS.
Similarly, compared with men who completed the
TICS, men who were still alive but declined partici-
pation (n=1625) were older (77.0 vs 76.3 years,
z=5.14, P<0.001), had higher tHcy concentrations
(13.4 vs 12.8mmol/L, z=4.52, P<0.001) and lower
MMSE scores at the time of blood sampling (27.0 vs
27.3, t= 4.59, P<0.001).
Discussion
The results of this study are consistent with the
hypothesis that high tHcy causes cognitive impair-
ment in later life. We found that the doubling of tHcy
Table 1 Cross-sectional characteristics of the study population
Variable Controls (n=1347) Cases (n=431) Statistic P value
Age, mean (s.d.) years 81.2 (3.5) 82.7 (3.9) z= 7.21 <0.001
Education, n (%) completed high school or better 807 (59.9) 171 (39.7) w
2=53.44 <0.001
Physical activity, n (%) 942 (69.9) 284 (66.0) w
2=2.30 0.129
Smoking, n (%) 838 (62.2) 285 (66.1) w
2=2.15 0.143
Alcohol, n (%) 459 (34.1) 136 (31.6) w
2=0.93 0.334
GDS, mean (s.d.) 1.61 (1.76) 2.11 (2.3) z= 4.07 <0.001
History stroke, n (%) 62 (4.6) 28 (6.5) w
2=2.44 0.119
History diabetes, n (%) 107 (7.9) 54 (12.5) w
2=8.34 0.004
History IHD, n (%) 123 (9.1) 43 (10) w
2=0.28 0.600
History hypertension, n (%) 341 (25.3) 136 (31.6) w
2=6.47 0.011
History of head injury, n (%) 207 (15.5) 66 (15.5) w
2=0 1.000
BMI, mean (s.d.) 26.5 (3.4) 26.5 (3.4) t= 0.00 0.999
Systolic BP, mean (s.d.) mm mercury 147.2 (20.1) 147.9 (21.2) t= 0.61 0.541
Diastolic BP, mean (s.d.) mm mercury 75.4 (10.2) 75.2 (11.3) t=0.37 0.714
Glomerular filtration rate, mean (s.d.) ml/min 78.5 (18.3) 77.8 (18.3) t=0.46 0.229
Cholesterol, mean (s.d.) mmol/l 4.9 (0.9) 4.9 (0.9) t=0.39 0.806
Low density lipoprotein, mean (s.d.) mmol/l 2.9 (0.8) 2.9 (0.8) t=0.42 0.790
Triglycerides, mean (s.d.) mmol/l 1.3 (0.7) 1.4 (.8) z= 0.38 0.701
Glucose, mean (s.d.) mmol/l 5.7 (1.4) 5.7 (1.4) t=0.44 0.663
TSH, mean (s.d.) mU/l 2.3 (1.5) 2.5 (2) z= 0.91 0.364
tHcy, mean (s.d.) mmol/l 12.6 (4.8) 13.3 (4.5) z= 3.75 <0.001
Abbreviations: BMI, body mass index; BP, blood pressure; GDS, geriatric depression scale; IHD, ischemic heart disease;
tHcy, total plasma homocysteine; TSH, thyroid stimulating hormone.
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the odds of cognitive impairment in men over the age
of 75 years, which was also 59% higher in men in the
upper quartile of tHcy compared with those in the
lowest quartile. In addition, we found that men with
the TT genotype of the MTHFR gene, which increases
basal tHcy, had 46% higher odds of cognitive
impairment than men with the CC genotype.
This study consists of a large community-based
sample with a relatively high number of cases, thus
giving the study sufficient power to investigate the
specified hypotheses. Limitations of this study
include the observational nature of the associations,
the inclusion of only men in the sample (although
there is no suggestion to date that tHcy may have a
gender-specific effect with regards to cognition),
confounding (for example, diet and use of B-
vitamins), and the possibility of reverse causality
(that is, changes in lifestyle amongst prevalent cases
of cognitive impairment that lead to high tHcy). We
attempted to minimize confounding by adjusting our
analyses for factors known to affect tHcy and
dementia risk (for example, age, gender, smoking,
education, alcohol use, etc.). We addressed the
problem of reverse causality in two different ways:
(1) by excluding from the analyses people with
evidence of cognitive impairment at the time of entry
into the study and (2) by investigating the association
Table 2 Cross-sectional characteristics of the study population according to MTHFR genotype
Variable CC (n=722) CT (n=699) TT (n=179) Statistic P value
Age, mean (s.d.) years 81.3 (1.0) 81.8 (1.0) 81.5 (1.0) F=2.89 0.056
Education, n (%) 399 (55.3) 393 (56.2) 91 (50.8) w
2=1.67 0.433
Physical activity, n (%) 508 (70.4) 477 (68.2) 129 (72.1) w
2=1.32 0.516
Smoking, n (%) 436 (60.4) 459 (65.7) 114 (63.7) w
2=4.28 0.118
Alcohol, n (%) 246 (34.1) 235 (33.6) 54 (30.2) w
2=1.00 0.606
GDS, mean (s.d.) 1.6 (1.8) 1.6 (1.9) 1.6 (1.8) F=1.33 0.264
History stroke, n (%) 40 (5.5) 31 (4.4) 10 (5.6) w
2=1.02 0.601
History diabetes, n (%) 69 (9.6) 69 (9.9) 9 (5.1) w
2=4.22 0.121
History IHD, n (%) 66 (9.1) 64 (9.2) 19 (10.6) w
2=0.40 0.817
History hypertension, n (%) 200 (27.7) 180 (25.8) 46 (25.7) w
2=0.78 0.677
History of head injury, n (%) 114 (15.9) 102 (14.8) 24 (13.6) w
2=0.70 0.705
BMI, mean (s.d.) 26.4 (3.5) 26.8 (3.5) 26.5 (3.1) F=2.57 0.077
Systolic BP, mean (s.d.) mm mercury 147.3 (20.4) 147.2 (20.4) 147.8 (20.9) F=0.07 0.935
Diastolic BP, mean (s.d.) mm mercury 75.1 (10.3) 75.4 (10.4) 75.2 (11.5) F=0.17 0.844
Glomerular filtration rate, mean (s.d.) ml/min 78.1 (16.7) 78.7 (20.0) 78.0 (18.2) F=0.21 0.814
Cholesterol, mean (s.d.) mmol/l 4.9 (1.0) 4.9 (0.9) 4.9 (0.9) F=0.54 0.583
Low density lipoprotein, mean (s.d.) mmol/l 2.9 (0.8) 2.9 (0.8) 2.9 (0.8) F=0.27 0.765
Triglycerides, mean (s.d.) mmol/l 1.2 (1.6) 1.2 (1.6) 1.2 (1.6) F=1.84 0.159
Glucose, mean (s.d.) mmol/l 5.7 (1.4) 5.7 (1.5) 5.7 (1.2) F=0.21 0.811
TSH, mean (s.d.) mU/l 2.0 (1.9) 2.0 (2.0) 1.8 (2.4) F=1.30 0.272
tHcy, mean (s.d.) mmol/l 11.8 (1.3) 12.3 (1.4) 12.5 (1.5) F=4.77 0.009
Abbreviations: BMI, body mass index; BP, blood pressure; GDS, geriatric depression scale; IHD, ischemic heart disease;
MTHFR, methylenetetrahydrofolate reductase gene; tHcy, total plasma homocysteine; TSH, thyroid stimulating hormone.
Table 3 Odds ratios (95% CI) of cognitive impairment according to tHcy and gene status
Crude model Adjusted for age and education Fully adjusted
a
tHcy 1.03 (1.01–1.05)
b 1.02 (0.99–1.04) 1.02 (0.99–1.04)
Doubling of tHcy 1.59 (1.24–2.03)
b 1.37 (1.06–1.78)
b 1.36 (1.02–1.82)
b
tHcyX15mmol/l 1.47 (1.14–1.89)
b 1.28 (0.98–1.67) 1.33 (0.99–1.78)
tHcy quartile 2 1.10 (0.80–1.51) 1.19 (0.86–1.64) 1.36 (0.96–1.91)
tHcy quartile 3 1.35 (0.99–1.84) 1.37 (0.99–1.87) 1.43 (1.02–2.01)
b
tHcy quartile 4 1.40 (1.03–1.91)
b 1.43 (1.04–1.96)
b 1.59 (1.10–2.28)
b
MTHFR CT 1.13 (0.88–1.45)
MTHFR TT 1.46 (1.01–2.11)
b
Abbreviations: MTHFR, methylenetetrahydrofolate reductase gene; tHcy, high total plasma homocysteine.
aAdjusted for age, education, depressive symptoms, physical activity, history of stroke, diabetes, ischemic heart disease and
hypertension, smoking, alcohol, head injury, renal function, thyroid function, serum cholesterol, low density lipoprotein and
triglycerides, fasting blood glucose, body mass index (bmi) and blood pressure at baseline (systolic and diastolic).
bP<0.05.
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tHcy and the development of cognitive impairment.
In both instances, our results suggest that high tHcy is
causally related to cognitive impairment.
It is possible that bias may have been introduced
because of the high number of men on whom baseline
assessments were done, but were unavailable for the
TICS assessment (53.8%). These men were older, had
higher tHcy concentrations and worse cognitive
function than those who completed the TICS. Hence,
our results may have been biased towards the null
hypothesis and this could have led to an under-
estimation of the effect-high tHcy on cognitive
impairment over time.
It is also conceivable that, by chance, our partici-
pants with high tHcy had other characteristics that
rendered them more vulnerable to cognitive decline,
such as the presence of the apolipoprotein-E geno-
type. As we did not collect such information, we are
unable to dismiss such a possibility outright. More-
over, we acknowledge that our definition of ‘caseness’
was based on a telephone-screening test for cognitive
impairment that, although sensitive, does not equate
to the clinical diagnosis of dementia.
25 Additionally,
the assessment of the exposure occurred only once,
and we were unable to take into account changes in
tHcy that may have taken place over time, although
presence of the MTHFR-C677T polymorphism is
consistent with prolonged exposure to higher basal
tHcy. Furthermore, there is evidence that a single
baseline measurement may underestimate the risk of
the outcome, because of regression dilution bias,
32 so
that our findings may be conservative. Finally, as
assessment with TICS was only available at the
follow-up assessment, we are unable to comment
on the potential impact of tHcy on cognitive decline
over time.
Case-control studies investigating this association
have reported similar results.
33,34 Clarke and collea-
gues examined 164 patients aged 55 years or older
with a clinical diagnosis of Alzheimer’s dementia,
including 76 with histologically confirmed disease
and compared these to 108 age-matched healthy
volunteers. Participants in the upper tertile
(>14mmol/l) of tHcy were twice as likely to have
AD compared with people in the lowest tertile and
four and a half times more likely to have histologi-
cally confirmed AD.
There may be a number of biological pathways by
which hyperhomocysteinemia causes cognitive im-
pairment and dementia. Elevated plasma homocys-
teine may be neurotoxic, an effect possibly mediated
by the activation of the N-methyl-D-aspartate recep-
tor.
35 Homocysteine is also a known risk factor for
cardiovascular disease,
36 having been implicated in
the causation of coronary artery disease, carotid
atherosclerosis and stroke.
37 Cardiovascular disease
is an important risk factor for both vascular dementia
and AD and may represent yet another mechanism
linking high plasma homocysteine to cognitive
impairment in later life.
38 In addition, methionine is
the immediate precursor of S-adenosylmethionine,
the methyl donor of numerous methylation reactions
in the brain. This includes the methylation of
phospholipids, nucleic acids, myelin and catechola-
mines.
39 Homocysteine also appears to interact with
the amyloid and tau pathways implicated in the
pathophysiology of AD.
40,41 Finally, high tHcy may
contribute to accelerate ageing, with experimental
evidence indicating that the lifespan of rats can
be extended through the use of a methionine deficient
diet.
42
The finding of an association between high tHcy
and cognitive impairment could have important
clinical consequences, as tHcy can be reliably and
safely reduced by the simple supplementation of B-
vitamins.
43 A number of mostly negative randomized
trials have investigated the association between
vitamin supplementation and cognitive decline in
people with and without dementia, although no trial
to date has examined whether the use of B-vitamins
can reduce the incidence of dementia in people
at risk.
10–13,44–46
This study has investigated the association between
tHcy and cognition in a large sample of elderly men
while controlling for a range of potential confounders
of the relationship and, additionally, by investigating
the association between the MTHFR-genetic poly-
morphism and cognition. Despite this, the best way to
try and definitively investigate the association be-
tween the two is through appropriately powered
randomized trials. There would be merit in large
population-based randomized trials of sufficient
duration, with the aim of establishing whether
homocysteine lowering with B-vitamins is able to
reduce the incidence of dementia.
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